Cargando…
Drug design and discovery in Alzheimer's disease /
Drug Design and Discovery in Alzheimer's Disease includes expert reviews of recent developments in Alzheimer's disease (AD) and neurodegenerative disease research. Originally published by Bentham as Frontiers in Drug Design and Discovery, Volume 6and now distributed by Elsevier, this compi...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Amsterdam, Netherlands :
Elsevier,
[2014]
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_ocn912421312 | ||
| 003 | OCoLC | ||
| 005 | 20231120112006.0 | ||
| 006 | m o d | ||
| 007 | cr cnu|||unuuu | ||
| 008 | 150630s2014 ne ob 001 0 eng d | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d N$T |d EBLCP |d OPELS |d IDEBK |d YDXCP |d OCLCF |d YDX |d OCLCO |d OCLCO |d OCLCQ |d CASUM |d OCLCO |d MERER |d OCLCO |d OCLCQ |d OCLCA |d BUF |d OCLCO |d OCLCQ |d U3W |d D6H |d OCLCQ |d WYU |d OCLCO |d OCLCQ |d OCLCO |d OCLCA |d S2H |d OCLCO |d VT2 |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO | ||
| 019 | |a 913334796 |a 918993990 |a 973375158 |a 1066520977 |a 1175610728 |a 1235839477 | ||
| 020 | |a 9780128039601 |q (electronic bk.) | ||
| 020 | |a 0128039604 |q (electronic bk.) | ||
| 020 | |a 9780128039595 |q (electronic bk.) | ||
| 020 | |a 0128039590 |q (electronic bk.) | ||
| 035 | |a (OCoLC)912421312 |z (OCoLC)913334796 |z (OCoLC)918993990 |z (OCoLC)973375158 |z (OCoLC)1066520977 |z (OCoLC)1175610728 |z (OCoLC)1235839477 | ||
| 050 | 4 | |a RC523 | |
| 060 | 4 | |a WT 155 | |
| 072 | 7 | |a HEA |x 039000 |2 bisacsh | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 072 | 7 | |a MED |x 012000 |2 bisacsh | |
| 082 | 0 | 4 | |a 616.8/31061 |2 23 |
| 245 | 0 | 0 | |a Drug design and discovery in Alzheimer's disease / |c edited by Att-ur-Rahman, FRS, Honorary Life Fellow, Kings College, University of Cambridge, UK and Muhammad Iqbal Choudhary, H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Pakistan. |
| 264 | 1 | |a Amsterdam, Netherlands : |b Elsevier, |c [2014] | |
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 504 | |a Includes bibliographical references and index. | ||
| 588 | 0 | |a Vendor-supplied metadata. | |
| 505 | 0 | |a Front Cover; Drug Design and Discovery in Alzheimer's Disease; Copyright; Contents; Preface; List of Contributors; Chapter 1: Pharmacotherapy of Alzheimer's Disease: Current State and Future Perspectives; Abstract; 1. Alzheimer's Disease -- Historic Overview; 2. Current Status and Prevalence of AD; 3. Risk Factors for AD; 4. Cholinergic Theory; 5. Cholinesterases; 6. Current Therapeutic Approaches to AD; 7. Conclusions; Acknowledgements; Conflict of Interest; References; Chapter 2: Challenges in Designing Therapeutic Agents for Treatingalzheimer's Disease-From Serendipity to Rationality. | |
| 505 | 8 | |a AbstractIntroduction; Alzheimer's Disease (AD); Challenges in Designing Alzheimer's Medicines; Symptomatic Drugs; Disease Modifying Drugs (Investigative Approaches); Rational Approaches to Design AD Drugs; Multi-Target-Directed Ligand (MTDL) Design Strategy; Concluding Remarks & Future Prospects; Acknowledgements; Conflict of Interest; Abbreviations; References; Chapter 3: Enzyme Inhibitors Involved in the Treatment of Alzheimer's Disease; Abstract; Introduction; Pathophysiology of Alzheimer Disease; Overview on Key Enzymes Involved in Alzheimer's Disease. | |
| 505 | 8 | |a Clinically Used Enzymes Inhibitors for Alzheimer's DiseaseCurrent Enzyme-Targeted Drug Development Foralzheimer's Disease; Conclusions; Acknowledgements; Conflict of Interest; Abbreviations; References; Chapter 4: Towards Small Molecules as Therapies for Alzheimer's Disease and Other Neurodegenerative Disorders; Abstract; Introduction to Neurodegenerative Diseases; Alzheimer's Disease: Etiology and the �-Amyloid Hypothesis; BACE1 and the �-Amyloid Hypothesis; The Evolution of BACE1 Inhibitors; BACE1 Inhibitors: Uncovering "Chemical Truffles" in Pre-Clinical Drug Discovery. | |
| 505 | 8 | |a HD and Mitochondrial DysfunctionThe Synergy Between Aggregation and Autophagy; Transcriptional Regulation; Other Biological Pathway Deficits; Perspectives for HD; Conclusive Remarks; Acknowledgements; Conflict of Interest; Abbreviations; References; Chapter 5: Multifunctional Enzyme Inhibition for Neuroprotection -- A Focus on MAO, NOS, and AChE Inhibitors; Abstract; Introduction; Monoamine Oxidase -- Isoforms and Function; Nitric Oxide Synthase (NOS) -- Isoforms and Structure; Acetylcholinesterase -- Structure and Function; Conclusion and Future Developments; Acknowledgements. | |
| 520 | |a Drug Design and Discovery in Alzheimer's Disease includes expert reviews of recent developments in Alzheimer's disease (AD) and neurodegenerative disease research. Originally published by Bentham as Frontiers in Drug Design and Discovery, Volume 6and now distributed by Elsevier, this compilation of the sixteen articles, written by leading global researchers, focuses on key developments in the understanding of the disease at molecular levels, identification and validation of molecular targets, as well as innovative approaches towards drug discovery, development, and delivery. Beginning with an. | ||
| 650 | 0 | |a Alzheimer's disease |x Chemotherapy. | |
| 650 | 0 | |a Alzheimer's disease |x Treatment. | |
| 650 | 0 | |a Drugs |x Design. | |
| 650 | 2 | |a Alzheimer Disease |x drug therapy |0 (DNLM)D000544Q000188 | |
| 650 | 2 | |a Drug Delivery Systems |0 (DNLM)D016503 | |
| 650 | 2 | |a Drug Design |0 (DNLM)D015195 | |
| 650 | 6 | |a Maladie d'Alzheimer |x Chimioth�erapie. |0 (CaQQLa)201-0330307 | |
| 650 | 6 | |a Maladie d'Alzheimer |0 (CaQQLa)201-0114128 |x Traitement. |0 (CaQQLa)201-0377521 | |
| 650 | 6 | |a M�edicaments |x Conception. |0 (CaQQLa)201-0203461 | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x General. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Clinical Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Diseases. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Evidence-Based Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Internal Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Chemotherapy. |2 bisacsh | |
| 650 | 7 | |a Alzheimer's disease |x Chemotherapy |2 fast |0 (OCoLC)fst00806536 | |
| 650 | 7 | |a Alzheimer's disease |x Treatment |2 fast |0 (OCoLC)fst00806591 | |
| 650 | 7 | |a Drugs |x Design |2 fast |0 (OCoLC)fst00898790 | |
| 655 | 4 | |a Internet Resources. | |
| 700 | 1 | |a Rahman, Atta-ur-, |d 1942- |e editor. | |
| 700 | 1 | |a Choudhary, Muhammad Iqbal, |e editor. | |
| 776 | 0 | 8 | |i Print version: |a Atta-ur-Rahman. |t Drug Design and Discovery in Alzheimer's Disease. |d Burlington : Elsevier Science, �2015 |z 9780128039595 |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780128039595 |z Texto completo |